home / stock / konef / konef news


KONEF News and Press, KetamineOne Capital Limited From 11/02/22

Stock Information

Company Name: KetamineOne Capital Limited
Stock Symbol: KONEF
Market: OTC
Website: wellbeingdigital.co

Menu

KONEF KONEF Quote KONEF Short KONEF News KONEF Articles KONEF Message Board
Get KONEF Alerts

News, Short Squeeze, Breakout and More Instantly...

KONEF - Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...

KONEF - Wellbeing Announces Definitive Agreement to Divest IRP Health

PURSUANT TO COMPLETION OF DUE DILIGENCE, WELLBEING WILL DIVEST ITS EQUITY STAKE IN IRP Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcar...

KONEF - Wellbeing Digital to Participate at this Years' Wonderland Miami Conference

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...

KONEF - Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...

KONEF - Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta's Move to Regulate the Use of Psychedelics

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...

KONEF - Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial

The psilocybin 1.5mg capsules are available for potential therapeutic use in non-ASD clinical trials, including but not limited to diabetes, heart disease, cancer, and post-traumatic stress disorder Wellbeing Digital Sciences Inc. (“ Wellbeing” or the ...

KONEF - The Marriage of Herbal Nutraceuticals and Psychedelics

Nutraceuticals have been getting a bad health and wellness rap for years. Most of the chatter is about them not being “real”; doctors ignore them in part because they have not gone through any FDA-approved clinical trials—even as their patients rave abou...

KONEF - Wellbeing Digital Signs LOI Manage Additional Clinics

With the Company’s extensive experience in this sector, we are eager to replicate the growth and profitability success of our clinics at additional sites within our clinical ecosystem Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ C...

KONEF - Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics

Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, includin...

KONEF - Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future

New Clinical Facility in London, Ontario Accelerates Research and Innovation Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company ...

Previous 10 Next 10